Amphastar Pharmaceuticals AMPH Non-cash interest expense

Non-cash interest expense at other companies

Amneal Pharmaceuticals, Inc.AMRX

——

HRO

HarrowHROW

——

Other financials

Income statement

See full

Revenue$171.2M+0.4%

Gross profit$70.3M-17.5%

Operating income$13.6M-63.5%

Net income$6.4M-74.6%

EPS (diluted)$0.14-72.5%

Balance sheet

See full

Cash & equivalents$170.9M-6.5%

Total debt$686.6M+5.2%

Total equity$445.5M—

Total assets$1.6B+1.3%

Cash flow

See full

Operating cash flow$47.8M+36.4%

CapEx$9.5M-11.1%

Free cash flow$38.3M+57.2%

Valuation

See full

Market cap$927.72M-19.9%

Enterprise value$1.44B-11.3%

P/E11.7×+3.5×

P/S1.3×-0.3×

Profitability

See full

Gross margin47.3%-3.2pp

Operating margin16.2%-10.4pp

Net margin11%-8.4pp

FCF margin18.8%-1.8pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amphastar Pharmaceuticals's non-cash interest expense?: Amphastar Pharmaceuticals (AMPH) reported non-cash interest expense of $761K in Q1 2026.